Zuellig Pharma

Zuellig Pharma, headquartered in Singapore and operating in the Research and development services industry, reported total greenhouse gas emissions of approximately 232.3 million kg CO2e in 2024. This figure includes about 14.7 million kg CO2e from Scope 1 emissions, approximately 22.2 million kg CO2e from Scope 2 market-based emissions (or 56.2 million kg CO2e location-based), and roughly 165.4 million kg CO2e from Scope 3 emissions. Notably, its 2024 Scope 3 emissions breakdown includes 79.3 million kg CO2e from purchased goods and services, 68.0 million kg CO2e from upstream transportation and distribution, 17.4 million kg CO2e from end-of-life treatment of sold products, and 14.3 million kg CO2e from fuel and energy related activities.

In 2023, Zuellig Pharma's total emissions were approximately 296.5 million kg CO2e, comprising about 10.5 million kg CO2e (Scope 1), 28.3 million kg CO2e (Scope 2 market-based, or 56.1 million kg CO2e location-based), and 257.6 million kg CO2e (Scope 3). The company's emissions have fluctuated, with a total of approximately 287.1 million kg CO2e in 2022, 430.1 million kg CO2e in 2021, and 402.5 million kg CO2e in 2020. Emissions data for Zuellig Pharma, including historical figures, are cascaded from its parent company, Zuellig Pharma Holdings, at cascade level 0.

Zuellig Pharma has committed to several reduction targets. It aims to reduce absolute Scope 1 and 2 GHG emissions by 42% by 2030, using a 2021 base year. Furthermore, the company pledges to reduce absolute Scope 3 GHG emissions from fuel and energy related activities, upstream transportation and distribution, and waste generated in operations by 25% within the same timeframe. The company also aligns with national targets for carbon neutrality by 2050 for Scope 1 and 2 emissions, reflecting goals from Hong Kong and broader national ambitions.